FDA’s 2026 Enforcement Priorities: What In-House Counsel Must Know [Video]

Short summary

The FDA's 2026 enforcement priorities span six key trends including monitoring online marketing claims, cracking down on telehealth platforms offering compounded GLP-1s, enforcing CGMP compliance, and scrutinizing food facility Foreign Supplier Verification Programs. Form 483 responses are under heightened scrutiny, and medical device manufacturers should prepare for increased QMSR enforcement. In-house counsel should watch for shifts under new FDA leadership.

• •FDA monitoring websites, social media, and podcasts for inappropriate marketing claims
• •Continued enforcement against telehealth platforms offering compounded GLP-1s
• •Form 483 responses under heightened scrutiny; device makers should prepare for QMSR enforcement

Generated with AI, which can make mistakes.